SCHEMBL680023

SCHEMBL680023

CCOC(=O)c1ccnn(-c2ccc(F)cc2)c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
APP P05067 1/20 0.48
MAPT P10636 1/20 0.48
ALDH1A1 P00352 6/20 0.48
RAB9A P51151 3/20 0.48
TSHR P16473 2/20 0.47
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
LMNA P02545 1/20 0.47
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
SLC5A1 P13866 1/20 0.46
SLC5A2 P31639 1/20 0.46
HPGD P15428 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
AXL P30530 1/20 0.44
POLB P06746 1/20 0.44
GAA P10253 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679990 0.81 KMT2A (0.53) MEN1KMT2AL3MBTL1APPMAPT
SCHEMBL13115613 0.79 MET (0.49) MEN1KMT2AAXLGAA
SCHEMBL2282783 0.79 AXL (0.47) L3MBTL1MAPTALDH1A1RAB9ANPC1
SCHEMBL680352 0.79 AXL (0.47) MEN1KMT2AL3MBTL1ALDH1A1LMNA
SCHEMBL6052641 0.78 ALDH1A1 (0.60) MAPTALDH1A1RAB9ATSHRNPC1
SCHEMBL28578776 0.77 TYK2 (0.52) L3MBTL1MAPTALDH1A1RAB9ASMN1; SMN2
SCHEMBL6052432 0.77 ALDH1A1 (0.59) MAPTALDH1A1RAB9ATSHRNPC1
SCHEMBL18256950 0.77 AXL (0.52) L3MBTL1ALDH1A1AXL
SCHEMBL1195700 0.76 ALDH1A1 (0.57) MAPTALDH1A1RAB9ATSHRNPC1
SCHEMBL12376653 0.76 AXL (0.52) AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE43878-E1 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2012-12-25 US disclosed
EP-2310382-B1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET LILLY CO ELI (US) 2012-02-22 EP disclosed
US-8030302-B2 Amidophenoxyindazoles useful as inhibitors of c-Met ELI LILLY AND COMPANY (US) 2011-10-04 US disclosed
EP-2310382-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET Eli Lilly & Company (US) 2011-04-20 EP disclosed
WO-2010011538-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY (US) 2010-01-28 WO disclosed
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET ELI LILLY AND COMPANY 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022529-A1 AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET MET, MYCBP, MYC MEN1 176/4885KMT2A 1681/4885L3MBTL1 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.